Finepoint Capital and Herbert Wagner report 5.7% RXO (RXO) ownership stake
Filing Impact
Filing Sentiment
Form Type
SCHEDULE 13G
Rhea-AI Filing Summary
Finepoint Capital LP and Herbert Wagner reported a significant passive stake in RXO, Inc. common stock on a Schedule 13G. They beneficially own 9,388,789 shares of RXO common stock, representing 5.7% of the class, with shared voting and dispositive power over all of these shares.
The percentage is based on 164,111,872 RXO shares outstanding as of November 4, 2025, as disclosed in RXO’s Form 10-Q for the quarter ended September 30, 2025. Finepoint acts as investment adviser to affiliated funds that directly hold the shares. The securities are certified as acquired and held in the ordinary course of business and not for the purpose of changing or influencing control of RXO.
Positive
- None.
Negative
- None.
FAQ
What RXO (RXO) ownership did Finepoint Capital disclose in this Schedule 13G?
Finepoint Capital LP and Herbert Wagner disclosed beneficial ownership of 9,388,789 RXO common shares, equal to 5.7% of the company’s outstanding stock. The stake is held through funds advised by Finepoint, with shared voting and dispositive power over all reported shares.
How did Finepoint’s RXO (RXO) ownership percentage of 5.7% get calculated?
The 5.7% ownership is based on 164,111,872 RXO common shares outstanding as of November 4, 2025, as reported in RXO’s Form 10-Q. Finepoint’s 9,388,789 shares divided by that outstanding share count results in the disclosed 5.7% stake.
Is Finepoint Capital’s RXO (RXO) stake intended to influence control of the company?
The filing certifies the RXO shares were acquired and held in the ordinary course of business, not for the purpose of changing or influencing control. The certification explicitly states they are not held in connection with any control-related transaction, subject to limited nomination-related activities language.
Who are the reporting persons in the RXO (RXO) Schedule 13G filing?
The reporting persons are Finepoint Capital LP and Herbert Wagner. Finepoint is a Delaware limited partnership and registered investment adviser to affiliated funds that hold RXO shares. Wagner is Finepoint’s founder and managing partner through FPCap LLC, which is Finepoint’s general partner.
When did Finepoint’s RXO (RXO) ownership position trigger this Schedule 13G filing?
The date of the event requiring the filing is December 31, 2025. That date reflects when Finepoint’s and Herbert Wagner’s beneficial ownership in RXO common stock reached the reportable level that necessitated submitting this Schedule 13G to the Securities and Exchange Commission.